ValuEngine downgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a research note published on Friday.

CLLS has been the topic of several other research reports. BidaskClub cut Cellectis from a sell rating to a strong sell rating in a research note on Friday, September 7th. Zacks Investment Research raised Cellectis from a hold rating to a buy rating and set a $25.00 price objective on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $48.00.

Shares of NASDAQ:CLLS opened at $22.00 on Friday. Cellectis has a 52-week low of $21.29 and a 52-week high of $38.85. The company has a market capitalization of $915.32 million, a P/E ratio of -7.91 and a beta of 1.76.

A number of hedge funds and other institutional investors have recently made changes to their positions in CLLS. FMR LLC boosted its position in Cellectis by 18.0% during the 2nd quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock valued at $119,949,000 after acquiring an additional 647,164 shares in the last quarter. BlackRock Inc. boosted its position in Cellectis by 259.7% during the 2nd quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock valued at $12,552,000 after acquiring an additional 320,340 shares in the last quarter. Nexthera Capital LP boosted its position in Cellectis by 64.7% during the 2nd quarter. Nexthera Capital LP now owns 548,212 shares of the biotechnology company’s stock valued at $15,509,000 after acquiring an additional 215,458 shares in the last quarter. Laurion Capital Management LP bought a new stake in Cellectis during the 2nd quarter valued at $5,658,000. Finally, Macquarie Group Ltd. bought a new stake in Cellectis during the 3rd quarter valued at $5,390,000. 27.36% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Read More: Depreciation

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.